Clinical Trial

Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.

Study acronym: FLIP-IMMUNO
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Prospective, observational, multi-site, single arm, exploratory pilot study, designed to prospectively assess the relationship between basal c-FLIP expression in M-MDSCs with clinical outcomes in patients treated with anti-PD-L1 monotherapy in a 1L mNSCLC setting, as well as evaluate changes in c-FLIP during treatment and correlate those changes with clinical outcomes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-26.
Trial Details
NCT Number NCT07051928
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Non Small Cell Lung Cancer
Enrollment 107 participants
Start Date 2025-07
Primary Completion 2027-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2025-07-09